Quantcast

Latest William K. Oh Stories

2014-06-15 08:20:51

LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/hormone_refractory_breast_cancer_global_clinical_trials_review_h1_2014.htmlHormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Hormone Refractory Breast Cancer Global Clinical Trials...

2014-04-15 08:28:19

Phase III Trial Now Recruiting Patients SANTA ROSA, Calif., April 15, 2014 /PRNewswire/ -- A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C® modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. "MCP has shown activity against prostate and other cancers in a number of previous studies, and toxicology...

2014-04-12 23:00:02

ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge collection of research reports.Full Report With TOC at http://www.researchmoz.us/metastatic-hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2014-report.html. Albany, NY (PRWEB) April 13, 2014 Researchmoz presents this most up-to-date research on...

2014-04-08 12:30:37

-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat(TM) prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States. An initial pilot study to be launched in April will examine 300 patient samples and is...

2014-02-11 08:30:37

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...

2013-09-24 11:18:06

Analysis of patient subset from RTOG 9202 A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Men with advanced prostate...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related